Join
Live feed
·
INSIDERFilingvia Quantisnow
Iovance Biotherapeutics Inc. logo

Chief Operating Officer Bilinsky Igor converted options into 12,307 shares and covered exercise/tax liability with 6,903 shares, increasing direct ownership by 5% to 111,148 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
Free account required

Sign up free to keep reading

Create a free Quantisnow account to read full insights, follow tickers, and get real-time alerts on filings, ratings, and regulatory news.

Sign up freeLog inNo credit card

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IOVA (Iovance Biotherapeutics Inc.) and more on Quantisnow.